Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study
Dmitri O. Grebennik, Kensei Tobinai, Madeline Duvic, Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, Alain H. Rook, Pierluigi Porcu, Sarah McCue Horwitz, Sean Whittaker, Y. Tokura, Maarten H. Vermeer, Pier Luigi Zinzani, Lubomir Sokol, Stephen Morris, Ellen Kim, Pablo L. Ortiz‐Romero, Herbert Eradat, Julia Scarisbrick, Athanasios Tsianakas, Craig A. Elmets, Stéphane Dalle, David C. Fisher, Ahmad Halwani, Brian Poligone, John P. Greer, Maria Teresa Fierro, Amit Khot, Alison J. Moskowitz, Karen M. Dwyer, Junji Moriya, Jeffrey S. Humphrey, Stacie Hudgens (2017). Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study. , 130(Suppl_1), DOI: https://doi.org/10.1182/blood.v130.suppl_1.817.817.
